{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:21:41Z","timestamp":1792686101229,"version":"4.5.0"},"reference-count":23,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,6,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Apixaban in patients with impaired renal function is supported by limited data. Landmark clinical trials evaluating apixaban in patients with atrial fibrillation and\/or acute venous thromboembolism excluded patients with creatinine clearance (CrCl) &amp;lt;25 mL\/min. This multicenter, retrospective chart review was conducted to evaluate the safety and effectiveness of apixaban compared with warfarin in patients with CrCl &amp;lt;25 mL\/min. Included patients were newly initiated on apixaban or warfarin for at least 45 days with a CrCl &amp;lt;25 mL\/min. Patients were evaluated for thrombosis and bleeding outcomes 6 months following initiation of anticoagulation. The primary outcome was the time to first bleeding or thrombosis event. A total of 128 patients met inclusion criteria in the apixaban group and 733 patients in the warfarin group. Time to first bleeding or thrombosis event was significantly different between the apixaban and warfarin groups. Cox proportional hazards model was conducted to control for potential confounding factors for the primary outcome. After controlling for atrial fibrillation and coronary artery bypass grafting, risk of thrombotic and bleeding events was lower in the apixaban group (hazard ratio, 0.47; 95% confidence interval, 0.25-0.92). There was not a statistical difference between time to thrombosis (83 days vs 54 days, P = .648), rate of thrombosis (5.5% vs 10.3%, P = .08), time to bleeding (46 days vs 54 days, P = .886), or rate of bleeding (5.5% vs 10.9%, P = .06). The severity of bleeding and thrombotic events was not different between groups. Apixaban may serve as a reasonable alternative compared with warfarin in patients with severe renal dysfunction.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000972","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T15:31:48Z","timestamp":1590679908000},"page":"2366-2371","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":42,"title":["Outcomes associated with apixaban vs warfarin in patients with renal dysfunction"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5701-269X","authenticated-orcid":false,"given":"Claudia","family":"Hanni","sequence":"first","affiliation":[{"name":"Pharmacy Department, Beaumont Health, Royal Oak, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Petrovitch","sequence":"first","affiliation":[{"name":"Pharmacy Department, Detroit Medical Center, Detroit, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Ali","sequence":"first","affiliation":[{"name":"Pharmacy Department, Beaumont Health, Royal Oak, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney","family":"Gibson","sequence":"first","affiliation":[{"name":"Pharmacy Department, Baycare Health Systems, St. Petersburg, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Giuliano","sequence":"first","affiliation":[{"name":"Wayne State University Eugene Applebaum College of Pharmacy, Detroit, MI;"},{"name":"Pharmacy Department, Ascension St. John Hospital, Detroit, MI; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Holzhausen","sequence":"first","affiliation":[{"name":"Pharmacy Department, Beaumont Health, Royal Oak, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Makowski","sequence":"first","affiliation":[{"name":"Pharmacy Department, Henry Ford Hospital, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Pallisco","sequence":"first","affiliation":[{"name":"Pharmacy Department, Detroit Medical Center, Detroit, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Patel","sequence":"first","affiliation":[{"name":"Pharmacy Department, Henry Ford Hospital, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Sutter","sequence":"first","affiliation":[{"name":"Pharmacy Department, Detroit Medical Center, Detroit, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"To","sequence":"first","affiliation":[{"name":"Pharmacy Department, Henry Ford Hospital, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Yost","sequence":"first","affiliation":[{"name":"Pharmacy Department, Detroit Medical Center, Detroit, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,5,28]]},"reference":[{"issue":"21","key":"2020060911255711300_B1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published correction appears in J Am Coll Cardiol. 2014;64(21):2305-2307]","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2020060911255711300_B2","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation: CHEST Guideline and Expert Panel Report","volume":"154","author":"Lip","year":"2018","journal-title":"Chest"},{"issue":"2","key":"2020060911255711300_B3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report [published correction appears in Chest. 2016;150(4):988]","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"issue":"1","key":"2020060911255711300_B4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/ndt\/gft209","article-title":"Haemostasis in chronic kidney disease","volume":"29","author":"Lutz","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2020060911255711300_B5","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1681\/ASN.2007111207","article-title":"Dilemmas in the management of atrial fibrillation in chronic kidney disease","volume":"20","author":"Reinecke","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"24","key":"2020060911255711300_B6","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","article-title":"Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II Registry","volume":"68","author":"Steinberg","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"2020060911255711300_B7","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"2020060911255711300_B8","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"2020060911255711300_B9","unstructured":"Eliquis (apixaban; package insert). Princeton, NJ: Bristol-Myers Squibb Company. Available at: https:\/\/packageinserts.bms.com\/pi\/pi_eliquis.pdf. Accessed 4 May 2020."},{"issue":"5","key":"2020060911255711300_B10","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/jcph.633","article-title":"Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban","volume":"56","author":"Chang","year":"2016","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"2020060911255711300_B11","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/jcph.628","article-title":"Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis","volume":"56","author":"Wang","year":"2016","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"2020060911255711300_B12","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1681\/ASN.2016090980","article-title":"Apixaban pharmacokinetics at steady state in hemodialysis patients","volume":"28","author":"Mavrakanas","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"2020060911255711300_B13","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s11239-018-1683-5","article-title":"Safety analysis of apixaban versus warfarin in patients with advanced kidney disease","volume":"46","author":"Bowie","year":"2018","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"2020060911255711300_B14","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/pace.13331","article-title":"Safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: meta-analysis [published correction appears in Pacing Clin Electrophysiol. 2018;41(7):879]","volume":"41","author":"Chokesuwattanaskul","year":"2018","journal-title":"Pacing Clin Electrophysiol"},{"issue":"3","key":"2020060911255711300_B15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.amjcard.2014.10.042","article-title":"Meta-analysis on risk of bleeding with apixaban in patients with renal impairment","volume":"115","author":"Pathak","year":"2015","journal-title":"Am J Cardiol"},{"key":"2020060911255711300_B16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ijcard.2016.09.129","article-title":"Efficacy and safety of novel anticoagulants versus vitamin K antagonists in patients with mild and moderate to severe renal insufficiency: focus on apixaban","volume":"225","author":"Pelliccia","year":"2016","journal-title":"Int J Cardiol"},{"issue":"2","key":"2020060911255711300_B17","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/rth2.12083","article-title":"Safety and effectiveness of apixaban compared to warfarin in dialysis patients","volume":"2","author":"Reed","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"6","key":"2020060911255711300_B18","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/1060028017694654","article-title":"Safety outcomes of apixaban compared with warfarin in patients with end-stage renal disease","volume":"51","author":"Sarratt","year":"2017","journal-title":"Ann Pharmacother"},{"issue":"11","key":"2020060911255711300_B19","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1177\/1060028018781853","article-title":"Safety and efficacy of apixaban versus warfarin in patients with advanced chronic kidney disease","volume":"52","author":"Schafer","year":"2018","journal-title":"Ann Pharmacother"},{"issue":"15","key":"2020060911255711300_B20","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.118.035418","article-title":"Outcomes associated with apixaban use in end-stage kidney disease patients with atrial fibrillation in the United States","volume":"138","author":"Siontis","year":"2018","journal-title":"Circulation"},{"issue":"4","key":"2020060911255711300_B21","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/phar.1905","article-title":"Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment","volume":"37","author":"Stanton","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"23","key":"2020060911255711300_B22","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"issue":"2","key":"2020060911255711300_B24","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1160\/TH16-07-0494","article-title":"Real-life treatment of venous thromboembolism with direct oral anticoagulants: the influence of recommended dosing and regimens","volume":"117","author":"Trujillo-Santos","year":"2017","journal-title":"Thromb Haemost"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/11\/2366\/1744177\/advancesadv2019000972.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/11\/2366\/1744177\/advancesadv2019000972.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T15:26:33Z","timestamp":1591716393000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/11\/2366\/457796\/Outcomes-associated-with-apixaban-vs-warfarin-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,28]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,6,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000972","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,28]]}}}